The efficacy of a serum carboxyterminal pyridinoline cross-linked telopeptide of type I collagen as a quantitative screening marker for bone metastases in patients with urological malignancies

Cancer Detection and Prevention

Volumn 27, Issue 1, 2003, Pages 14-18

  Okamura, Takehiko ^a   Akita, Hidetoshi ^a   Tatsura, Hiroyuki ^b   Kawai, Noriyasu ^c   Nagata, Daisuke ^c   Azemoto, Masataka ^d   Iwase, Yutaka ^d   Kohri, Kenjiro ^c  

^a Meijo Hospital   (Japan)

^b Nagoya City Higashi General Hospital   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^d Aihoku Hospital   (Japan)

Author keywords

Bone metastasis; ICTP; ROC curve; Urological malignancy

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BLOOD; BONE TUMOR; COMPARATIVE STUDY; HUMAN; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; ROC CURVE; URINARY TRACT CANCER;

AGED; ALKALINE PHOSPHATASE; BONE NEOPLASMS; COLLAGEN; COLLAGEN TYPE I; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS;

EID: 0037225018     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00172-1     Document Type: Article

References (18)

1. Stepan JJ, Mikulecky M, Bek V, et al. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastasis, and patients with primary hyperparathyroidism. Neoplasia 1989;36:495-501.
2. Coleman RE, Whitaker KB, Moss DW, et al. Biochemical prediction of response of bone metastases to treatment. Br J Cancer 1988;58:205-10.
3. Takeuchi SI, Yoshida KI. Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastasis. Jpn J Urol 1994;85:1521-7.
4. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 1998;34:240-5.
5. Tähtelä R, Tholix E. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PIPC, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 1996;16:2289-94.
6. Koizumi M, Takahashi S, Ogata E. Bone metabolic markers in bone metastasis of breast cancer. Int J Clin Oncol 1999;4:331-7.
7. Horiguchi T, Tachikawa S, Kondo R, et al. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer. Jpn J Clin Oncol 2000;30:174-9.
8. Kylmälä T, Tammela T, Risteli L, et al. Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites: a controlled trial of the Finnish prostate cancer group. Eur J Cancer 1993;29:821-5.
9. Yoshida K, Sumi S, Arai K. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer 1997;80:1760-7.
10. Maeda H, Koizumi M, Yoshimura K. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 1997;157:539-43.
11. Eriksen EF, Chaqrles P, Melsen F, et al. Serum markers of type I collagen formation and degradation in metabolic bone disease: collelation with bone histomorphometry. J Bone Miner Res 1993;8:127-32.
12. Risteli J, Elomaa I, Niemi S, et al. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal teropeptide of I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
13. Risteli J, Elomaa I, Niemi S, et al. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
14. Zweig MH, Campbell G. Receiver operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
15. Kairisto V, Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand J Clin Lab Invest 1995;55(Suppl 222):37-41.
16. Elomaa I, Virkkunen P, Risteli L, et al. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992;66:337-41.
17. Akimoto S, Furuya Y, Akakura K, et al. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis. Endocline J 1998;45:97-104.
18. Koizumi M, Ogata E. Bone metabolic markers in metastatic bone tumors. Cancer J 1998;3:137-40.